Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms
Pedro Gonçalves, João R. Araújo, Fátima Martel
European Neuropsychopharmacology (2014) Vol. 25, Iss. 1, pp. 1-16
Closed Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Madhubhashinee Dayabandara, Raveen Hanwella, S. S. Ratnatunga, et al.
Neuropsychiatric Disease and Treatment (2017) Vol. Volume 13, pp. 2231-2241
Open Access | Times Cited: 256
Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses
David C. Henderson, Brenda Vincenzi, Norte García Andrea, et al.
The Lancet Psychiatry (2015) Vol. 2, Iss. 5, pp. 452-464
Closed Access | Times Cited: 251
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Marco Carli, Shivakumar Kolachalam, Biancamaria Longoni, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 3, pp. 238-238
Open Access | Times Cited: 158
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, et al.
Journal of Atherosclerosis and Thrombosis (2023) Vol. 31, Iss. 6, pp. 641-853
Open Access | Times Cited: 136
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Spyridon Siafis, Dimitrios Tzachanis, Myrto Samara, et al.
Current Neuropharmacology (2017) Vol. 16, Iss. 8, pp. 1210-1223
Open Access | Times Cited: 130
Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy
Catherine G. Coughlin, Katherine A. Blackwell, Christine A. Bartley, et al.
Obstetrics and Gynecology (2015) Vol. 125, Iss. 5, pp. 1224-1235
Open Access | Times Cited: 115
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder
Evdokia Anagnostou, Michael G. Aman, Benjamin L. Handen, et al.
JAMA Psychiatry (2016) Vol. 73, Iss. 9, pp. 928-928
Open Access | Times Cited: 106
Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care
Suzanne Moore, David Shiers, Blánaid Daly, et al.
Acta Psychiatrica Scandinavica (2015) Vol. 132, Iss. 2, pp. 109-121
Closed Access | Times Cited: 101
Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses
Chiara Possidente, Giuseppe Fanelli, Alessandro Serretti, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 152, pp. 105298-105298
Open Access | Times Cited: 35
The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain
Sarah Kanji, Trehani M. Fonseka, Victoria S. Marshe, et al.
European Archives of Psychiatry and Clinical Neuroscience (2017) Vol. 268, Iss. 1, pp. 3-15
Closed Access | Times Cited: 74
Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives
Raghunath Singh, Yashika Bansal, Bikash Medhi, et al.
European Journal of Pharmacology (2018) Vol. 844, pp. 231-240
Closed Access | Times Cited: 69
Secondary dyslipidemia: its treatments and association with atherosclerosis
Hidekatsu Yanai, Hiroshi Yoshida
Global Health & Medicine (2020) Vol. 3, Iss. 1, pp. 15-23
Open Access | Times Cited: 51
Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
Raghunath Singh, Nicolette Stogios, Emily R. Smith, et al.
Therapeutic Advances in Psychopharmacology (2022) Vol. 12
Open Access | Times Cited: 30
Mechanism and treatments of antipsychotic-induced weight gain
Wujie Ye, Jingyu Xing, Zekai Yu, et al.
International Journal of Obesity (2023) Vol. 47, Iss. 6, pp. 423-433
Closed Access | Times Cited: 16
Circulating Levels of Hormones, Lipids, and Immune Mediators in Post-Traumatic Stress Disorder – A 3-Month Follow-Up Study
Mladen Jergović, Krešo Bendelja, Ana Savić Mlakar, et al.
Frontiers in Psychiatry (2015) Vol. 6
Open Access | Times Cited: 59
Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats
Xuemei Liu, Zhixiang Wu, Jiamei Lian, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 46
Drug‐Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism
Uchenna Anyanwagu, Iskandar Idris, Richard Donnelly
Clinical Pharmacology & Therapeutics (2015) Vol. 99, Iss. 4, pp. 390-400
Closed Access | Times Cited: 42
Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment
Vidar M. Steen, Silje Skrede, Tatiana Polushina, et al.
European Neuropsychopharmacology (2016) Vol. 27, Iss. 6, pp. 589-598
Closed Access | Times Cited: 42
Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis
Priyanthi B. Gjerde, Ingrid Dieset, Carmen Simonsen, et al.
Schizophrenia Research (2017) Vol. 197, pp. 253-260
Open Access | Times Cited: 37
Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance‐pharmacodynamic study
Spyridon Siafis, Georgios Papazisis
British Journal of Clinical Pharmacology (2018) Vol. 84, Iss. 10, pp. 2405-2414
Open Access | Times Cited: 33
Adiposity in schizophrenia: A systematic review and meta‐analysis
Emily R. Smith, Raghunath Singh, Jiwon Lee, et al.
Acta Psychiatrica Scandinavica (2021) Vol. 144, Iss. 6, pp. 524-536
Closed Access | Times Cited: 25
The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications
Hui Chen, Ting Cao, Bikui Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
Pharmacogenetics of Risperidone‐Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder
Chonlaphat Sukasem, Natchaya Vanwong, Pornpen Srisawasdi, et al.
Basic & Clinical Pharmacology & Toxicology (2018) Vol. 123, Iss. 1, pp. 42-50
Open Access | Times Cited: 29
Brain insulin action: Implications for the treatment of schizophrenia
Sri Mahavir Agarwal, Chantel Kowalchuk, L Castellani, et al.
Neuropharmacology (2019) Vol. 168, pp. 107655-107655
Closed Access | Times Cited: 28
Global gray matter morphometry differences between children with reading disability, ADHD, and comorbid reading disability/ADHD
Audreyana Jagger‐Rickels, Michelle Y. Kibby, Jordan Constance
Brain and Language (2018) Vol. 185, pp. 54-66
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top